Free tool
FAERS Monitor: Clarinex-D 12 Hour
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021313 or its brand name (Clarinex-D 12 Hour, Desloratadine, Pseudoephedrine Sulfate). Reports on generic versions are filed under their own applications.
Reports
39
Serious
23
59% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity4
- nausea4
- dizziness3
- feeling abnormal3
- insomnia3
- malaise3
- product dose omission issue3
- pruritus3
- rash3
- urticaria3
- abdominal discomfort2
- anxiety2
- arthralgia2
- chest pain2
- cough2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,120 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 4 | 11.1 | 4.4 | 28 |
| urticariaSignal | 3 | 9.7 | 3.3 | 16 |
| feeling abnormalSignal | 3 | 6.8 | 2.3 | 10 |
| abdominal discomfort | 2 | 6.4 | 1.7 | 5 |
| insomniaSignal | 3 | 6.1 | 2.0 | 8 |
| chest pain | 2 | 5.8 | 1.5 | 4 |
| product dose omission issueSignal | 3 | 5.5 | 1.9 | 7 |
| pruritusSignal | 3 | 4.2 | 1.4 | 5 |
| cough | 2 | 3.8 | 1.0 | 2 |
| anxiety | 2 | 3.8 | 1.0 | 2 |
| rash | 3 | 3.7 | 1.3 | 4 |
| malaise | 3 | 3.7 | 1.2 | 4 |
| dizziness | 3 | 3.2 | 1.1 | 3 |
| nausea | 4 | 2.7 | 1.1 | 3 |
| arthralgia | 2 | 2.6 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.